The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Adam Sharp
No Relationships to Disclose
 
Johann De Bono
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; ImCheck therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Acai Therapeutics; Amgen; Amunix (Inst); Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics (Inst); Boehringer Ingelheim (Inst); CellCentric; Crescendo Biologics (Inst); Daiichi Sankyo; Dark Blue Therapeutics (Inst); Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Harpoon therapeutics; ImCheck therapeutics; Immunic Therapeutics; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; MetaCurUm; Myricx Pharma; Novartis; Nurix (Inst); Oncternal Therapeutics; Orion; Pfizer (Inst); Qiagen; Sanofi Aventis GmbH (Inst); Sierra Oncology; Taiho Oncology; Takeda (Inst); Tango Therapeutics (Inst)
Speakers' Bureau - AstraZeneca
Research Funding - Amgen (Inst); AstraZeneca (Inst); CellCentric (Inst); Crescendo Biologics (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunic Therapeutics (Inst); Janssen (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MetaCurUm (Inst); MorphoSys (Inst); Myricx (Inst); Nurix (Inst); Oncternal Therapeutics (Inst); Orion (Inst); Pfizer (Inst); Sanofi Aventis GmbH (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; AstraZeneca; Bayer; Cellcentric; Daiichi Sankyo; Genentech/Roche; GlaxoSmithKline; Halda Therapeutics; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi
 
Frank Cackowski
Honoraria - GU Oncology Now, Mashup Media LLC
 
Begoña Mellado
No Relationships to Disclose
 
Jorge Esteban Villarrubia
Research Funding - Astellas Pharma (Inst)
Expert Testimony - Astellas Pharma; Bristol Myers Squibb Foundation; Merck; MSD Oncology; Recordati
Travel, Accommodations, Expenses - Ipsen; Johnson & Johnson/Janssen; MSD; Roche
 
Sara Perez Ramirez
Honoraria - Eisai; GlaxoSmithKline; IPSEN; Merck
Consulting or Advisory Role - Eisai; GlaxoSmithKline; MSD Oncology
Travel, Accommodations, Expenses - AstraZeneca Spain; GlaxoSmithKline; Ipsen; MSD Oncology
 
David Lorente-Estelles
Consulting or Advisory Role - Astellas Pharma; AstraZeneca Spain; Bayer; Janssen Oncology; Sanofi
Speakers' Bureau - Astellas Pharma; Astellas Pharma; AstraZeneca; Bayer; BMSi; Ipsen; Janssen Oncology; MSD Oncology
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen Oncology; Pfizer; Sanofi
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen; Loxo/Lilly; Merck KGaA; MSD Oncology; MSD Oncology (Inst); Pfizer (Inst); Pfizer/EMD Serono; Roche; Roche (Inst); Seagen
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Hakim Mahammedi
Honoraria - AAA/Endocyte/Novartis; Astellas Pharma; AstraZeneca; Bayer Schering Pharma; BMS; Curium Pharma; Eisai; Janssen-Cilag; MSD Oncology; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BMS; Eisai; Novartis
Travel, Accommodations, Expenses - Bayer; BMS GmbH & Co. KG; Ipsen; Janssen-Cilag; Novartis; Pfizer
(OPTIONAL) Uncompensated Relationships - Curium Pharma
 
Gwenaelle Gravis
Consulting or Advisory Role - AAA/Endocyte/Novartis (Inst); Astellas Pharma (Inst); Bayer (Inst); BMS (Inst); Curium Pharma (Inst); Eisai (Inst); IPSEN (Inst); Janssen (Inst); Pfizer (Inst)
Speakers' Bureau - AAA/Endocyte/Novartis (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD (Inst)
Expert Testimony - BAYER (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - AAA/Endocyte/Novartis; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; MSD
 
Simon Pacey
Consulting or Advisory Role - AstraZeneca (Inst); Elsevier (Inst); Roche/Genentech (Inst)
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Guardant Health (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Simon Crabb
Honoraria - Astellas Pharma; AstraZeneca; Ipsen; Janssen; Merck
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; DualityBio; Janssen; Merck; MSD; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Elypta (Inst); Roche (Inst); Veracyte (Inst)
Travel, Accommodations, Expenses - Bayer; Novartis
 
Genelle Brower
Employment - Celcuity
Stock and Other Ownership Interests - Celcuity
 
Michael Nessly
Employment - Celcuity
Stock and Other Ownership Interests - Celcuity
 
Sarah Mutka
Employment - Celcuity
Stock and Other Ownership Interests - Celcuity
 
Alex Cacovean
Employment - Celcuity
Stock and Other Ownership Interests - Celcuity
 
Igor Gorbatchevsky
Employment - Celcuity
Stock and Other Ownership Interests - Celcuity
 
Karim Fizazi
No Relationships to Disclose